Abstract Obesity, diabetes and their associated diseases are some of the greatest challenges that the world health care systems already face and with prospects of overburdening their capacities and funding. Due to decreased energetic expenditure and increased caloric intake, particularly in saturated fats, the number of people afflicted by said conditions is increasing by the day. Due to the failure, to this day, to effectively and ubiquity prevent and revert these diseases, the research into new compounds and therapeutic strategies is vital. In this review, we explain the most common dietary models of obesity and diabetes and the novel avenues of research we believe will be taken in the next few years in obesity and diabetes research. We primarily focus on the role of mitochondria and how the modulation of mitochondrial function and number as well as several promising therapeutic strategies involving metabolic regulators can positively affect the obese and diabetic status.
Introduction

Diabetes and obesity
Metabolic diseases are rapidly increasing their prevalence and becoming one of the most important and costly problems affecting the world's population and health care systems. Diabetes and its associated complications have become a worldwide epidemic, with estimates of 382 million sufferers in 2013 and 592 million people by 2,035 (International Diabetes Foundation, www.idf.org). Type 2 diabetes (T2D) is the most common form of metabolic dysfunction and is characterized by high levels of circulating glucose and overall insulin resistance. Complications from diabetes include cardiovascular diseases, optical, neuronal and renal disorders, among others (Brownlee and Cerami 1981) . The incidence of T2D is typically age dependent, as more than 20 % of people older than 60 years of age have diabetes compared to only about 8 % of the population as a whole (Styskal et al. 2012) .
The strongest predictor of the development of this pathology is obesity, which is rapidly increasing worldwide mainly due to an unbalanced diet and reduced physical exercise (Mann et al. 2004; Diamond 2003; Hu et al. 2001; Caterson et al. 2004) . Furthermore, genetic factors also play a role in the development of obesity and T2D (Uusitupa 2005) . Obesity and T2D may also share the same genetic profile; in other words, the same genetic variations may increase the risk of both obesity and T2D (Uusitupa 2005) .
Insulin secretion defects and insulin resistance can also be genetically determined, whereas insulin sensitivity is highly responsive to alterations in lifestyle, which means that more physical activity, permanent weight reduction and a more balanced and adequate diet typically result in improved insulin sensitivity. Therefore, long-term obesity associated with insulin resistance and high-fat and/or sugar content diets may also, on the long run, through diverse mechanisms, result in exhaustion of b-cells, insulin resistance and cellular damage. Nevertheless, it is still unknown how much of this can be modulated by genetic factors.
Between 80 and 90 % of people with T2D are obese, so around 80 % of individuals with T2D have metabolic syndrome (Laaksonen et al. 2004 ). The number of obese children and adolescents is increasing, and the incidence of T2D or impaired glucose tolerance is common among young people with marked obesity .
Excessive fat deposition leads to several metabolic alterations, from insulin resistance, hepatic steatosis, hyperlipidemia and cardiovascular diseases, to name a few. Obesity is responsible for the impairment of many inflammatory, endocrine and other pathways. It is of a great importance to understand how factors such as obesity can lead to diabetes and insulin resistance in order to expand therapeutic options for future treatment of these diseases. Although intensively studied, being a multipathological condition that involves several organs means that the mechanisms behind the development of these pathologies are yet to be fully understood (Cornier et al. 2008 ).
Molecular mechanism
The diabetic state is characterized by persistent substrate abundance in circulation. There is a stable excess of the following metabolic substrates: glucose, free fatty acids or FFA (Boden 2003) , triglycerides or TG (Frohlich and Steiner 2000) , lactate (Kelley and Mandarino 1990) , ketone bodies (Avogaro et al. 1996) or amino acids (Vannini et al. 1982) . This leads to a decrease in the activities of several metabolic pathways, since their end products are less required. As such, increased substrate (like glucose) availability leads to an increased insulin release and also to an increment in oxidative stress as, for example, a higher production of reactive oxygen species (ROS) (Hammes et al. 2003) . Increased oxidizable substrates availability leads to increased mitochondrial membrane potential which, in turn, leads to diminished oxidative phosphorylation velocity and, thus, increased possibility for electrons to ''jump'' from the respiratory chain directly to molecular oxygen, resulting in heightened ROS generation (Rolo and Palmeira 2006) . In turn, the diminished substrate utilization and increase in ATP is accompanied by an increment in NADH, in both the cytosol and in mitochondria. NAD and NADH values are kept relatively constant within a cell, for the ratio between them is considered a marker of metabolic status (Teodoro et al. 2013a ). The increased substrate availability leads, at least in the early stages of nutrient excess exposure, to an accumulation of NADH (by both increasing the rate of NAD ? reduction and by decreasing NADH oxidation rate, as previously mentioned), leading to a decrease in metabolic activity, for example at the mitochondrial oxidative phosphorylation (OXPHOS) system and other NAD ? -dependent enzymes. This reduced NAD ? /NADH ratio can autofeed itself by increasing the available circulating substrates. In fact, NADH stimulates many anabolic pathways. For example, fatty acid synthesis is stimulated in the presence of excess NADH (Dahlen and Porter 1968) . As mentioned before, an increase in the NADH content also causes an augmented reductive state of the mitochondrial respiratory chain, with consequent increase in ROS generation (Kukielka et al. 1994) . Oxidative stress has been extensively proposed as a major cause for diabetic complications, where ROS are key players. ROS can derive from several sources, as the OXPHOS, glucose autoxidation and enzymatic activity (as NAD(P)H oxidase, lipooxygenase, cytochrome P450 monooxygenases and nitric oxide synthase (NOS)). Contributing to the increase in substrate utilization (through alterations on the insulin receptor activity), ROS augment their synthesis in an autofeedback loop (Lawlor and Alessi 2001; Vincent et al. 2002) . In a normal cell, complexes I and III of the mitochondrial respiratory chain are the cell's main ROS production sites; however, in a diabetic state, complex II overcomes these as the main ROS producer (Nishikawa et al. 2000) .
Diverse studies support the hypothesis that oxidative stress promotes particular pathologies associated with diabetes. Hence, it is suggested that further investigation using antioxidant mutant mouse models could be extremely useful in the search for treatments for these pathologies related to metabolic dysfunction. For example, it has been shown that retinal damage associated with diabetes is increased in mice lacking the key antioxidant enzyme superoxide dismutase 1 (Sod1) (Dong et al. 2006) , as is the rate of diabetes-induced cataract formation (Olofsson et al. 2009 ). Conversely, mice that overexpress Sod1 show reduced diabetes-induced retinopathy (Dong et al. 2006; Berkowitz et al. 2009 ). But Sod1 is not the only antioxidant enzyme studied, for mice overexpressing catalase in the kidney shows reduced renal disease associated with diabetes (Brezniceanu et al. 2008) , and mice overexpressing the mitochondrial Sod2 in the heart shows reduced diabetes-induced left ventricular hypertrophy .
Mitochondria
Mitochondria are the powerhouses of the eukaryotic cell. Being the main ATP generation site, mitochondria play a key role in the regulation of several aspects of cell biology such as metabolism, redox status, calcium signaling and programmed cell death, to name a few (Schatz 1995) . Mitochondria host, as a whole or in part, critical bioenergetic pathways, including the tricarboxylic acid (TCA) cycle, OXPHOS, the urea cycle, lipidic b-oxidation and ketogenesis.
Mitochondrial dysfunction in T2D and obesity
Mitochondrial dysfunction has been implicated in the pathogenesis of chronic metabolic diseases characterized by insulin resistance such as obesity and T2D. There is evidence that mitochondrial dysfunction may occur independently of significant changes in circulating concentrations of glucose (Boudina et al. 2005; Sloan et al. 2011) , arising potentially from lipotoxicity or oxidative stress that may predate significant hyperglycemia (Sloan et al. 2011; Niemann et al. 2011) . Studies have shown that insulin resistance is associated with mitochondrial dysfunction, such as reduced mitochondrial number and decreased ATP production (Kelley et al. 2002; Petersen et al. 2003) . Several studies are consistent with the idea that increased caloric intake and/or obesity is associated with increased mitochondrial superoxide production. There is evidence that treatment of cell cultures with free fatty acids increases ROS production, indicating that the elevation of fatty acids in circulation may provide an additional source of excess OXPHOS substrates through increased fatty acid oxidation (Kahn and Flier 2000) .
In animal models in which obesity was induced through high-nutrient feeding, levels of oxidative stress and damage are significantly increased. Levels of protein carbonylation and protein-bound 4-hydroxynonenal (a marker of lipidic peroxidation) are elevated in the adipose tissue (Sayre et al. 2006) . Malondialdehyde levels (indicators of increased reaction of ROS with polyunsaturated fatty acids, PUFA) in the liver of animals fed a high-fat diet are also significantly elevated (Ling et al. 2007) . These are but a few examples of all the literature available, but all these data clearly show that obesity is associated with a pro-oxidant environment and increased oxidative damage. This association is complex and multifactorial, but alterations in mitochondria function appear to play a significant role (Table 1) . Mittler et al. 2011) . Under normal conditions, the oxidation of glucose or fatty acids to generate ATP through mitochondrial respiration results in the production of superoxide as a by-product of the electron transport chain (ETC) (Brownlee 2001 ). Mitochondria are the major sites of ROS generation in the cell, as a result of imperfectly coupled electron transport associated with OXPHOS (Boveris et al. 1976; Takeshige and Minakami 1979; Turrens et al. 1985) . The outcome is a particular susceptibility of mitochondria to oxidative damage. Electrons released from the ETC (Skulachev 1996; Lambert and Brand 2004) . The amplitude of the electrochemical proton gradient, which is known as respiratory control, regulates the overall rate of electron transport in the respiratory chain. When caloric intake is excessive, the electrochemical potential difference generated by the proton gradient is high, or in conditions of inhibition of the ETC complexes, the life of superoxide generating electron transport intermediates, such as ubisemiquinone, is prolonged (Skulachev 1998) . This occurs because the transmembrane proton gradient and the membrane potential inherently govern the activity of the respiratory chain complexes as proton pumps. If sufficiently high, the energetic release of the electronic transport across the ETC is no longer sufficient to accumulate protons against their gradient. As such, the electronic transport slows down, giving electrons higher chances of reaching O 2 and directly reduce it, generating O2 Á-.
Increased ROS production has been shown in mitochondria isolated from skeletal muscle, kidney, liver and adipose tissue from high-fat-fed or obese animals (Anderson et al. 2009; Ruggiero et al. 2011; Raffaella et al. 2008; Curtis et al. 2010 ).
Obesity, diabetes, mitochondria and aging
Due to the improvements in medicine, food access and alterations in lifestyle patterns, it comes as no surprise to realize that aging-related diseases have become the most abundant cause of death in human populations, at least in the developed world (Villareal et al. 2005; Ahima 2009 ). Metabolic syndrome, with its associated complications (as obesity, diabetes, cardiovascular diseases, to name a few), is positively correlated with aging in humans, due to the fact that aging tissues have higher rates of ROS generation, genetic instability, and inflammatory processes. These are all been demonstrated to relate to obesity and diabetes (expertly reviewed in Hotamisligil 2006; Russel and Kahn 2007) . Some of these effects have been linked to telomere shortening and oxidative damage to explain the genetic instability portion, for it has been shown that telomere shortening is accelerated by diabetes (Fuster and Andrés 2006) and that diabetes causes a galloping ROS generation increment (Valko et al. 2007 ). In fact, the telomere-obesity link is such an important one, and various works have reported several characteristics of said link (reviewed in Tzanetakou et al. 2012) . A recent work (Minamino et al. 2009 ) proposed that the alterations in white adipose tissue linking obesity and aging in a genetic mice model of obesity were result of heightened activity of p53. Unsurprisingly, the same work reports that mice lacked telomerase (the enzyme responsible for maintaining telomere size) had increased insulin resistance in response to either a high-fat diet or high-sucrose diet, when compared with normal control animals in the same conditions. They also presented increased levels of inflammation and macrophage infiltration in the adipose tissue (Minamino et al. 2009 ). As such, there appears to be a clear link between obesity, diabetes and aging-related diseases.
But it is not just the adipose tissue to relate these phenomena, for insulin resistance in the liver (Petersen et al. 2003) , skeletal muscle (Petersen and Shulman 2006) , pancreas (Tschen et al. 2009 ) and the brain (Parrott and Greenwood 2007) , to name a few, has also been related to aging-related characteristics. All these works leave an important question to be answered: Are these relationships breakable and their effects reversible? To supply and answer to these questions could revolutionize modern medicine and healthcare.
It can also be expected that mitochondrial function impairment is also heavily involved in the aging process. In fact, mitochondrial DNA (mtDNA) mutations have been related to not only diminished metabolic function, but also an accelerated aging phenotype (Larsson 2010; Lee and Wei 2012) . One recent work has demonstrated that the metabolic status of the animal also causes mitochondrial alterations in aging ). These characteristics are also present in mitochondria from obese and diabetic individuals, in various key metabolic tissues as the liver, skeletal muscle and adipose tissue (Teodoro et al. 2008 (Teodoro et al. , 2013b Patti and Corvera 2010; Gomes et al. 2012 ). As such, it comes as no surprise that the only known strategy to increase healthy longevity (calorie restriction) has also been shown to positively regulate mitochondrial function (Lee and Wei 2012) . However, this is not without questioning, for seemingly paradoxical demonstrations of altered mitochondrial function and number appear to contribute improved health and longevity in situations of obesity and diabetes Scialo et al. 2013 ). However, a careful analysis of the data demonstrates that, despite the fact that a TFAM deletion ) does indeed decrease mtDNA numbers, it does not affect mitochondrial content. Also, by downplaying mitochondrial respiratory chain complex I activity, this deletion increases uncoupled respiration which, in turn, causes more substrates to be utilized . Surprisingly, these animals are also diet-induced obesity resistant and appear to live and healthier than their control counterparts. As such, further studies are required to elucidate these matters.
Models and diets
High-fat diets
Diet is one of the main environmental factors that contribute to the development of an obese phenotype. Along with reduced exercise, augmented caloric intake and increase in several key nutrients as high-sodium intake have lead to a dramatic elevation in the prevalence of obesity. Due to their metabolic similarity with humans, animal rodent models are useful tools for studying obesity, as they will readily increase weight when fed high-fat diets and their metabolic alterations mimic ours, for the most part.
High-fat diets (HFD) typically contain about 32-60 % of calories from fat. From a nutritional perspective, a human diet of 60 kcal % fat would be considered extreme but these are commonly used to induce rapidly induce obesity in rodents, in order to reduce experimental time courses (Ghibaudi et al. 2002; Johnston et al. 2007) .
A HFD is associated with body weight increase, fat deposition throughout various organs and marked insulin resistance in animal models. Before significant increases in peripheral fat deposition occur, HFD typically increase liver fat levels as well as hepatic insulin resistance, which normally happens within days (Samuel et al. 2004) .
The source of dietary fat can also modify the phenotype. Examples of these are the effect of polyunsaturated fats that increase liver fat oxidation and induce expression of proinflammatory genes (Lee et al. 2007) ; as examples, when compared with butter fat, olive oil reduced hepatic triglyceride accumulation and fish oil reduced liver cholesterol levels (Hussein et al. 2007 ).
Fatty acids can affect phenotype through a variety of mechanisms, such as gene expression, eicosanoid production and membrane receptor function. However, not all fat is equally harmful, for the health benefits of low-dose PUFA's supplementation such as omega-3 fatty acids have been demonstrated. In animals fed similar amounts of fat, those fed diets containing fish oil (rich in these PUFAs) did not gain as much weight as those fed diets with more saturated fat (Ikemoto et al. 1996; Wang et al. 2002) and were more insulin sensitive (Buettner et al. 2006) . By multiple mechanisms of action, dietary phospholipids of marine origin might thus substantially prevent and/or improve an obese phenotype and lead to the prevention and treatment strategies for obesity-associated metabolic disorders. Some works show that dietary LC n-3 PUFA administered as phospholipids from marine fish cause improved metabolic responses than triglycerides in high-fat diet-induced obese mice. Even in small doses supplementation, it increases its bioavailability, whereas more efficacious depleting of the arachnoid acid content in phospholipids augmented anti-inflammatory molecules (EPEA, DHEA) production and decreased endocannabinoids AEA and 2-AG production . Also, Horakova and collaborators work emphasized the idea that diet supplementation with n-3 LC-PUFA contributed to a higher efficacy of TZDs, and other insulinsensitizing and hypolipidemic pharmaceuticals treating obesity and type 2 diabetes (Horakova et al. 2012 ).
High-fructose diets
An excess intake of refined carbohydrates is associated with increased weight gain, hypertriglyceridemia and insulin resistance in humans and animal models (Daly et al. 1997; Basciano et al. 2005) . Purified diets containing around 60-70 % of their calories as fructose (HFrD) or sucrose are capable of elevating TG and glucose production in the liver, ultimately leading to insulin resistance and hypertriglyceridemia relative to diets containing glucose as the main carbohydrate source (Daly et al. 1997; Basciano et al. 2005) . Usually, rodent chow diets contain only 4 % sucrose and less than 0.5 % of free fructose with most carbohydrate as both digestible starch and non-digestible fiber from grain sources. In contrast, low-fat purified diets can contain higher levels of sucrose, and this will depend heavily on the formula being used. It is possible to modify purified diets by manipulating the carbohydrate sources to promote metabolic syndrome while maintaining essential nutrients at recommended levels.
Fatty liver or steatosis is characterized by the accumulation of fat in the cytoplasm of hepatocytes derived from adipocytes, intestinal absorption or hepatic lipogenesis (Haque and Sanyal 2002; Browning and Horton 2004) . Non-alcoholic fatty liver diseases (NAFLD) are associated with obesity and T2D and are increasing, rapidly reaching epidemic proportions.
MCD and CD diets
As with many human diseases, fatty liver in rodents is also diet inducible. A methionine and choline-deficient (MCD) diet, a choline-deficient diet (CD) or a high-fat diet (HFD) are examples. Different dietary approaches produce different severities of disease along the NAFLD spectrum and likely work by unique mechanisms.
MCD diets will rapidly induce measurable hepatic macrovesicular steatosis in rodents by 2-4 weeks and lead to inflammation and fibrosis (Sahai et al. 2004 , Weltman et al. 1996 . Typically, a MCD diet contains about 20 % fat by energy.
MCD diet causes weight loss in animal models (in contrast to other high-fat models) or in humans and also averting insulin resistance (Kirsch et al. 2003; Rinella and Green 2004) . It also contains sucrose, which induces de novo lipogenesis and triglyceride synthesis. Pickens and collaborators showed that despite inducing the same overall level of hepatic fat accumulation, fructose was more effective than glucose at inducing hepatocellular injury in mice fed MCD diets for 21 days (Pickens et al. 2010) .
A choline-deficient diet also induces fatty liver in rodents in the absence of methionine deficiency. CD diets induce steatosis, inflammation and fibrosis over 10 weeks (Teodoro et al. 2008; Fujita et al. 2010) , while not leading to marked hepatitis or cirrhosis but the development of hepatocellular carcinoma.
The work conducted by Raubenheimer and co-workers used a CD diet in mice to manipulate liver fat content without affecting adipose fat stores to explore the role of liver fat accumulation in the insulin resistance and glucose intolerance of diet-induced obesity, uncovering that liver fat accumulation per se does not cause insulin resistance during high-fat feeding and that choline deficiency may shunt potentially toxic-free fatty acids toward innocuous storage triglyceride in the liver. (Raubenheimer et al. 2006) .
Focusing on the importance of mitochondria, we have previously investigated the impact of fatty liver on mitochondrial function in animals fed a choline-deficient diet over time. The fat accumulation causes a severe impairment of mitochondrial function, but more importantly, it also triggers a response mechanism, designed to withstand the challenge created by the steatosis, on the bioenergetic level. This study showed that mitochondria play a central role in the development of the non-alcoholic steatosis, particularly on the oxidative phosphorylation efficiency level (Teodoro et al. 2008) . Petrosillo and colleagues also demonstrated that impairment of complex I activity after 30 weeks of feeding with a choline-deficient diet is caused by ROS-dependent cardiolipin peroxidation (Petrosillo et al. 2007) .
A choline-deficient L-amino acid-defined (CDAA) diet leads to the development of typical non-alcoholic steatohepatitis (NASH)-like pathology, with lobular inflammation and fibrosis in a relatively short period of time (Takeuchi-Yorimoto et al. 2013 ). Steatosis and inflammation improved in a rat model of CDAA (choline-deficient Lamino acid-defined) diet-induced NASH on exchange for a CSAA (choline-supplemented L-amino acid-defined) diet, but persistent fibrosis, evidences of continued oxidative stress, hypoxia, and neovascularization, were still noted (Takeuchi-Yorimoto et al. 2013) .
Differences between models
The mechanisms involved with liver fat accumulation on CD diets may be different from those at work during MCD diet feeding (Kulinski et al. 2004) . Distinctly from the MCD model, fatty liver induced by a CD diet is not associated with weight loss, which might make CD diets more advantageous than MCD. After 7 weeks, the MCD diet induces higher scores of liver inflammation and steatosis than the CD diet (Veteläinen et al. 2007 ). But the CDfed rats gained weight, were insulin resistant and had higher plasma lipids than the MCD group animals (Veteläinen et al. 2007 ). When fed for equal intervals of time, HFD feeding results in significantly lower liver fat levels compared to what accumulates on an MCD diet (Romestaing et al. 2007 ). HFD feeding does not produce liver fibrosis and only mild steatosis as compared to MCD diets (Anstee and Goldin 2006) .
The work conducted by Cong and co-workers (Cong et al. 2008 ) modifies a HFD (60 % of calories) to simultaneously contain low levels of methionine and choline. C57BL/6 mice were fed the diet for 23 weeks and developed obesity, insulin resistance, dyslipidemia as well as liver steatosis, inflammation and fibrosis. In C57BL/6 mice, animals consuming both HFD-and fructose-/ sucrose-enriched drinking water developed hepatic fibrosis while a group consuming HFD alone did not (Kohli et al. 2010 ). The addition of cholesterol to a HFD increases liver fat levels, signs of liver damage and produces macro-and microvesicular steatosis compared to HFD alone, in the LDLR (-/-) mouse (Subramanian et al. 2011) . In Sprague-Dawley rats, vitamin D deficiency within a HFD worsened NAFLD versus HFD alone (Roth et al. 2012 ).
Therapeutic strategies
Introduction
For most obese patients, the most common way to counteract obesity is a combination of one or more therapeutic strategies, based on:
• Diet and lifestyle • Surgery • Pharmacological approach Obviously, to switch and maintain a low-calorie healthier diet and some form of physical exercise is key to most anti-obesity treatments. Easier said than done, not just due to relapse into old habits, but also because obese people have more difficulty to perform physical exercise and, in some cases, the moderate but constant exercise required for noticeable effects can be harmful (e.g., patients with cardiac impairments, atherosclerosis). As such, the development of a ''magic bullet'' or therapeutic strategy that could lead to decreased obesity with minimal effort is extremely attractive, albeit probably unlikely to exist.
If exercise and diet are difficult and/or are not producing any noticeable effects, it is possible for the practitioner to prescribe a pharmacological compound to aid/drive the improvement of obesity, usually by attacking the obesityassociated T2D. Unfortunately, such compounds are usually not very effective, since they can lead to increased obesity (e.g., thiazolidinediones, TZDs) or are not very effective on the long run (e.g., insulin secretagogues). As such, it comes as no surprise that the development of cutting edge compounds and therapies could vastly increase the metabolic status of obese/diabetic patients.
In extreme cases, one effective (although risky) strategy is based on bariatric surgery or the reduction of stomach volume. Gastric bypass, among other procedures, can have a dramatic effect on body weight, but is also dependent on lifestyle changes and carries all the risks and costs of surgical procedures.
As such, the search continues for the magic bullet. Candidates are tested, either of chemical or biological origin, new or well known, individually or in combination, to try to unveil which can cause the great breakthrough in the twenty-sirst century epidemic. The new drugs must act in one of three different ways: It will reduce appetite, reduce nutrient absorption or increase the basal metabolic rate. In this review, we will explore some of the novel strategies being currently tested.
Commonly used drugs
Phentermine is a commonly used drug prescribed to obese individuals for short-term use, in combination with diet and exercise (Nelson and Gehlert 2006) . It is an appetite suppresser based on the chemical structure of amphetamine, and, as such, it comes with no surprise that overuse can lead to several complications, as addiction and cardiovascular problems (Yanovski 2005) . There are currently various classes of regularly prescribed drugs to treat obesity on for long-term use, most notably sibutramine and orlistat.
The first is a serotonin and noradrenaline reuptake inhibitor (also chemically similar to amphetamine, but with a distinct mechanism of action-forced secretion versus reuptake inhibition), which limits food intake by giving a sensation of satiety (Heal et al. 1998) . It has been related to various cases of hypertension, cardiovascular complications and strokes, being withdrawn from the market in several countries, but it is still available in the United States.
Orlistat is a stable, potent pancreatic lipase inhibitor, with capacity to reduce obesity and prevent the onset of T2D (Torgerson et al. 2004) . It has, unsurprisingly, side effects, most notably steatorrhea, lipid-soluble vitamins malabsorption and possibly liver damage. To counter this, manufacturers advise patients to reduce fat intake, which, to some extent, beats the purpose of the compound.
Lorcaserin is a serotonin receptor agonist; thus, their activation on the hypothalamus leads to proopiomelanocortin release and weight loss through satiety, a mechanism not entirely dissonant from Sibutramide and other amphetamine-like compounds (Smith et al. 2008) , without the cardiotoxic side effects. Other serotonin receptor agonists such as fenfluramine and dexfenfluramine were highly effective as weight-loss drugs, but had to be removed from the market due to severe cardiac toxicity (Rothman and Baumann 2009) .
Phentermine has also been used in combination with topiramate, a strategy focused on satiety as described above combined with the anorexic side effects of topiramate, an anticonvulsant (Gadde et al. 2011) .
Rimonabant tackles the problematic in a different fashion. It is an antagonist of the cannabinoid receptor CB1, thus leading to food intake suppression (Fong and Heymsfield 2009) . It has been since removed from the market (due to side effects such as depression), but it pointed to the study of CB1 receptors on the fight against obesity.
Metformin, a common anti-diabetic agent (inhibits hepatic gluconeogenesis and increases muscular glucose uptake) has also been shown to decrease obesity, albeit as a secondary effect (Bray and Greenway 1999) . Other antidiabetic compounds can also lead to decreased obesity, but mostly as an indirect effect.
These are some of the most known anti-obesity drugs in use or discontinued in the last 20 years. The focus was primarily on achieving satiety or decreasing absorption, with sometimes encouraging results. Wong et al. (2012) show that the most promising new compounds currently on test are strapped by the same mechanisms and ideas. Thus, the development of compounds that act in all new ways is essential.
New approaches to an old problem
To come up with new therapeutic strategies that fall out of the range of previously utilized ones, one must contemplate different targets for acting upon. The above-mentioned drugs all fall on the scope of nutrient malabsorption (typically by inhibiting pancreatic lipase) or on altered neuronal signaling into tricking the organism to think it has had a full meal. We will now briefly elaborate on some interesting metabolic modulators that have been showing promising results in basic science works.
Sirtuins and AMPK, nutrient sensors
Sirtuins are a class of NAD ? -dependent deacetylases. By being dependent on the levels of oxidized NAD, sirtuin activity on gene transcription can be classified as a nutrient-sensitive action. Sirtuins activity as gene transcription modulators has been explored in various fields of investigation, from aging, to obesity, diabetes and Alzheimer's, to name a few (Yamamoto et al. 2007 ). Obviously, our focus here is on its ability to modulate metabolism.
The first data on the importance of SirT1 on metabolic regulation rose from SirT1-null mice, which demonstrated decreased insulin release, while overexpression of SirT1 causes increased insulin response to glucose (Moynihan et al. 2005) . Also, SirT1 deacetylates and thus activates peroxisome proliferator-activated receptor-c (PPARc) coactivator-1a (PGC-1a), a known master regulator of metabolism and mitochondrial biogenesis, whose activity is directly related to improved metabolic status (Nemoto et al. 2005) . Paradoxically, SirT1 inhibits uncoupling protein-2 (UCP2) expression, leading to increased mitochondrial coupling and thus reducing substrate utilization (Moynihan et al. 2005) . Conversely, PPARc's expression is downregulated by SirT1, leading to decreased adipogenesis and increased lipolysis (Picard et al. 2004 ). SirT1 activation of PGC-1a at brown adipocytes leads to increased mitochondrial biogenesis and thus increased thermogenic dissipation of excess nutrients (Lagouge et al. 2006 ). There are many other excellent works on SirT1 effects on metabolic regulation, which fall out of the scope of this review (see Yamamoto et al. 2007 ). These works are sometimes conflicting and make it difficult to understand what are the effects of SirT1 on metabolism. In fact, until very recently, the role of resveratrol (the most famous natural SirT1 activator) was questioned . SirT1 is also required for resveratrol beneficial effects, independent of the AMP-activated kinase (AMPK), another metabolic sensor (discussed below) (Price et al. 2012) .
SirT1 is the most famous and most studied sirtuin, but is far from being the only one. Another extremely important sirtuin is the normally mitochondrial native SirT3. The expression of SirT3 in white and brown adipose tissue (WAT and BAT, respectively) is induced by calorie restriction and cold exposure, respectively. The most interesting fact about SirT3 is that its constitutive expression leads to increased levels of PGC-1a and UCP1, thus making it a very attractive target for obesity reduction (Figs. 1, 2) .
Other effects of sirtuins exist, and other sirtuins have metabolic activity (e.g., SirT4 regulates insulin levels). However, except for resveratrol, practically no other agonist (specific or unspecific) for any sirtuin exists or is studied. As such, research unto new compounds that either mimic (with stronger activity) resveratrol or just compounds that modulate other sirtuins can lead to novel antiobesity and anti-diabetic drugs (Milne et al. 2007 ). One example is berberine, a traditional Chinese medicine compound that we have shown to improve obesity and mitochondrial function , with a strong involvement of SirT3 (Teodoro et al. 2013b) .
AMPK is an important metabolic sensor and regulator being involved in, among other effects, glucose uptake, lipidic b-oxidation and mitochondrial biogenesis, with vast effects on several organs, ranging from the liver to brain, Fig. 1 Schematic representation of the convergence of pathways of the proposed therapeutic targets. The modulations of the activity of both AMPK and sirtuins (as, for example, the discussed Sirt1) lead to a potent activation of PGC-1a which, in turn, binds to an increase in the transcriptional activity of key target transcription factors. One example is PPARc, a key transcription factor for metabolism. By acting on these targets, it is possible to elucidate molecular pathways and unveil therapeutic targets for exploration in the near future Fig. 2 The possibility of generating brown-like cells (''brite'' adipocytes) from white adipocyte depots is an attractive therapeutic strategy, for these cells have an immense potential for energy consumption, rather than energy storage. As such, an isolated or combination therapy that can lead to the increase in ''brite'' cell content can cause a massive alteration of one's metabolic status from WAT and BAT to skeletal muscle, i.e., all metabolically-relevant tissues (Winder 2001) . Since AMP activates AMPK, a rise in this adenosine nucleotide (with concomitant decrease in ATP) signals the cell to begin energyburning processes in order to generate ATP. As paralleled by NAD ? and SirT1, this property (and subsequent downstream effects) can be explored (and have been extensively studied) for obesity management. While SirT1 deacetylates proteins and histones, AMPK phosphorylates and alters proteins' activity (either increasing or decreasing) (Hardie et al. 2012) . AMPK has a similar effect to insulin, for it promotes GluT1 activation and Glut4 migration to the cellular membrane and thus increased glucose uptake and oxidation (Barnes et al. 2002; Pehmøller et al. 2009) . AMPK also appears to mediate fatty acid uptake in cardiac cells (Habets et al. 2009 ). But AMPK not only improves the uptake of nutrients, it also leads to increased oxidation of said nutrients, mainly by the inhibition of acetyl-CoA carboxylase (ACC) and thus increase in mitochondrial import of fatty acids (Merrill et al. 1997) and by increasing the glycolytic rate (Marsin et al. 2002) .
Another key effect of AMPK is on mitochondrial biogenesis. Unsurprisingly, AMPK phosphorylates and activates PGC-1a, thus leading to increased mitochondrial content, particularly in skeletal muscle (Winder et al. 2000) . Finally, AMPK can also activate (and be activated) by SirT1, by increasing cellular NAD ? levels (Cantó et al. 2010) .
As with sirtuins, these are but some effects of AMPK on metabolism (AMPK is also involved in many other biological functions-see Hardie et al. 2012) . AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) is the well-known AMPK synthetic agonist, but studies on its effects on the long-term activation of AMPK (for a continuous therapeutic use) are surprisingly lacking.
Thiazolidinediones (TZDs)
TZDs (or how they are also known, glitazones) are a class of anti-diabetic agents that activate PPARc, promoting its heterodimerization with the retinoid X receptor (RXR) and leading to gene transcription. This leads to various effects, not all beneficial, which puts the use of such compound into perspective. Nevertheless, the overall global effect is a potent insulin resistance decrease (Cariou et al. 2012) . Among these effects, TZDs are known to increase insulin sensitivity, promote adiponectin release and decrease of inflammatory cytokines. Conversely, they are also known to lead to adipocyte differentiation and increased lipogenesis, as well as decreasing circulating leptin levels, thus increasing food intake. These effects are confusing at best, and given the natural agonists of PPARc (e.g., polyunsaturated fatty acids, PUFA), that also demonstrate beneficial actions, one is tempted to think that the story behind PPARc is still mostly untold. In WAT, PPARc activation by TZDs leads to increased lipid uptake and triglyceride deposition (Hevener et al. 2003) . On a first glance, this might seem a bad thing, but the removal of fat from circulation and, most importantly, preventing its deposition on the liver and skeletal muscle is immensely beneficial in terms of insulin resistance, in what is known as the ''lipid steal hypothesis.'' Also at the WAT level, an increase in adiponectin synthesis and decrease in inflammatory cytokines contribute to improved insulin sensitivity (Yu et al. 2002; Weisberg et al. 2003) . TZDs also appear to improve hepatic steatosis, fibrosis and inflammation. This might seem surprising, even paradoxical, for TZDs increase hepatic fat deposition, and thus, one would believe that it would increase steatosis. In fact, WAT fat deposition stimulated by TZDs outweighs fat deposition in the liver, with the overall result being an improvement on hepatic steatosis (Belfort et al. 2006) . PPARc agonism by TZDs also improves atherosclerosis, by reduction of inflammation and circulating cholesterol (Rigamonti et al. 2008) . Finally, despite the fact that there is no PPARc expression in skeletal muscle, these global metabolic effects improve muscle metabolism and insulin sensitivity.
Despite these promising data, TZDs have, by the most part, removed from the market due to severe hepatotoxicity and suspected cardiotoxicity. Since it appears that there is a dose-dependent relationship between TZDs and their side effects, one would think that it would be a simple case of reducing the dosage, which can be a hard act to balance. Dual PPAR agonism (a and c) is an interesting therapeutic strategy that has the benefits of PPARc activation and PPARa stimulation of lipid oxidation; however, some compounds with dual PPAR agonism activity have already been shelved due to carcinogenesis and cardiotoxicity (Rubenstrunk et al. 2007 ). Finally, it is possible to modulate PPARc activity in other ways. PPARc is phosphorylated (causing a decrease in its insulin-sensitizing effects, but not on the adipogenic effects) by cyclin-dependent kinase 5 (CDK5). By targeting CDK5 alone or in simultaneous treatment with a PPARc agonist might be a powerful therapeutic strategy for the future (Choi et al. 2011) . As its name implies, PPARc is also regulated by PGC-1a (Puigserver et al. 1999 ) and has a negative regulatory relationship with SirT1, which begs for further studies and the comprehensive understanding of all these interactions (Picard et al. 2004; Han et al. 2010 ).
Brown adipose tissue and ''brite'' cells
Brown adipose tissue, BAT, has evolved into being a primordial source of heat generation in newborns and small mammals, by presenting a high content on UCP1-expressing mitochondria (UCP1 is actually a hallmark protein of BAT) (Cannon and Nedergaard 2004) . When activated, BAT generates a high metabolic rate, sustained by a rather large rate of substrate oxidation, which are obtained both from its lipid droplets and from circulation (Bartelt et al. 2011 ). As such, the overactivation of BAT could prove a highly effective therapeutic strategy for obesity. It was thought that BAT was not present in adult humans, voiding such therapeutic approaches. However, this has since been shown erroneous, and as such an interest in non-shivering thermogenesis as a mean to thwart obesity has boomed in recent years (Whittle 2012) . However, Vosselman and collaborators quickly ended such hopes by demonstrating that, despite present, adult human BAT is hardly an effective way to reduce obesity (Vosselman et al. 2012) . While one might rashly scrap this promising therapeutic approach, it should be made to notice that adipocytes are highly plastic cells. This means that, given the right stimuli, white adipocytes can be, to some extent, converted into brown-like cells, the so-called ''brite'' or beige adipocytes (the opposite, i.e., the conversion of brown into brite is also possible). As such, the next ''big thing'' in metabolic research is the conversion of white into brown adipocytes, thus leading to increased basal metabolic rates, burning more fuel and decreasing obesity. The ways by such phenomena occur, and what are the regulators and effectors fall out of the scope of this work. Instead, we decided to focus on novel ways to induce a ''brite'' phenotype.
Most therapeutic strategies that reduce adiposity in white adipocytes produce metabolic alterations that are common to what is described to happen in ''brite'' induction, i.e., the activation of PPARa and induction of lipolysis, leptin treatment and induction of mitochondrial biogenesis (Flachs et al. 2013) . These changes are normally associated with UCP1 induction and non-shivering thermogenesis. Interestingly, UCP1-null mice are obesity resistant when exposed to cold, but not at thermoneutrality (Anunciado-Koza et al. 2008) . To make matters worse, the work by Nedergaard and Cannon (2013) calculates that, despite the massive increase in UCP1 expression in WAT (that arises from virtually zero), the overall contribution of these newly formed ''brite'' cells to the body's basal metabolic rate is neglectable at best. This is confirmed by our recent work that demonstrates that a powerful anti-obesity agent, the bile acid chenodeoxycholic acid (CDCA), is able to reduce obesity in mice in, to some extent, an UCP1-independent fashion (Teodoro et al. 2014) . As such, these works suggest that some other pathways are at play here. Flachs et al. (2011) suggest that n-3 PUFA anti-obesogenic effects are not UCP1 dependent, nor are when combined with calorie restriction, but are rather caused by increased activity of the triglyceride/free fatty acid cycle (TG/FFA cycle), a so-called metabolic futile cycle, for it consumes energy while not requiring the generation of products. This cycle could be behind many anti-obesogenic effects of countless compounds, whose effects are clear, but mechanisms are not. Research unto these metabolic pathways is probably going to become a hot topic for obesity research in the near future.
Concluding remarks
Obesity, T2D and their associated conditions have become one the most pressing healthcare problems, to the point of being considered a global pandemy. As such, an efficient therapeutic approach for these diseases is a research priority. Despite all the efforts and previous strategies, this approach still eludes researchers and practitioners. We have demonstrated, in this review, the most commonly used animal dietary models for research in obesity and T2D, highlighting some of their characteristics and key points. In line with this, we also focused in past and current therapeutic strategies and explained why they have failed or are not as efficient. As such, we focused on 3 key targets for future research that we believe conveys the most promising ideas to thwart these diseases. We focused on SirT1 and AMPK, metabolic sensors and key metabolic regulators, and their interaction with PGC-1a, a known metabolic master regulator. We have also reviewed the most current knowledge on the possibility of modulating WAT into simulating brown adipocytes and, thus, induce energy expenditure.
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